Regulatory Updates
Page 3 • 5 itemsTrack global pharma regulatory policy changes, FDA, EMA, and other agency guidelines impacting drug development and market access. Stay ahead.
NMPA GMP Standards: Key Updates and Impact on Foreign Pharma Manufacturers
This article explores key updates to NMPA GMP standards and their significant implications for foreign pharmaceutical manufacturers in the Chinese market.
NMPA Accelerated Approval Orphan Drugs: Impact & Future Trends in China
This article delves into the NMPA's accelerated approval process for orphan drugs, focusing on its implications for rare disease treatments in China.
Pompe Disease Treatments APAC: Market Growth and Regulatory Insights
This article delves into the evolving landscape of Pompe Disease treatments in the APAC region, highlighting market growth and key regulatory developments.
PMDA SAKIGAKE Designation: Expediting Drug Approval in Japan
The PMDA SAKIGAKE Designation streamlines the approval process for drugs like XYZ, enhancing access to innovative therapies for patients in Japan.
NMPA Accelerated Drug Approvals: Key Policy Changes & Market Impact
Explore the recent NMPA policy changes on accelerated drug approvals and their significant impact on the market, particularly for treatments like XYZ Drug for cancer.